1. Amciderm
2. Amcininide
3. Cl 34,699
4. Cyclocort
5. Cyclort
6. Penticort
7. Triamcinolone 16,17-cyclopentylidenedioxy-21-acetate
1. 51022-69-6
2. Cyclocort
3. Amcinonidum
4. Cl-34699
5. Triamcinolonacetatcyclopentanonid
6. Cl 34699
7. Visderm
8. Mls000028656
9. Mls001333715
10. Chebi:31199
11. 423w026ma9
12. Nsc-758620
13. Amcinonido
14. Smr000058920
15. [2-[(1s,2s,4r,8s,9s,11s,12r,13s)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1'-cyclopentane]-8-yl]-2-oxoethyl] Acetate
16. [2-[(4r,8s,9s,11s,12r,13s)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1'-cyclopentane]-8-yl]-2-oxoethyl] Acetate
17. Amcinonida
18. Amcinonidum [inn-latin]
19. Amcinonido [inn-spanish]
20. Cyclocort (tn)
21. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11-hydroxy-, (11.beta.,16.alpha.)-
22. Amcinonide (jan/usp/inn)
23. Unii-423w026ma9
24. Ncgc00095071-01
25. (11?,16?)-21-(acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11-hydroxypregna-1,4-diene-3,20-dione
26. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-(cyclopentylidenebis(oxy))-9-fluoro-11-hydroxy-, (11.beta.,16.alpha.)-
27. Einecs 256-915-2
28. Amcinonide [usan:usp:inn:ban:jan]
29. Amcinonide [mi]
30. Amcinonide [inn]
31. Amcinonide [jan]
32. Opera_id_1472
33. Amcinonide [usan]
34. Amcinonide [vandf]
35. Amcinonide [mart.]
36. Schembl4720
37. 1,4-pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate
38. Amcinonide [usp-rs]
39. Amcinonide [who-dd]
40. Dsstox_cid_25905
41. Dsstox_rid_81217
42. Dsstox_gsid_45905
43. 19alpha-fluor-11beta,21-dihydroxy-16alpha,17alpha-(tetramethylen)methylendioxy-1,4-pregnadien-3,20-dion 21-acetat
44. 9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-acetal With Cyclopentanone, 21-acetate
45. Mls001146959
46. Mls002695893
47. Amcinonide, Analytical Standard
48. Gtpl7060
49. Amcinonide [orange Book]
50. Chembl1200732
51. Dtxsid6045905
52. Amcinonide [usp Monograph]
53. Hms2235k23
54. Hms3715d11
55. 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-acetal With Cyclopentanone, 21-acetate
56. Amy38534
57. Hy-b1197
58. Zinc3977777
59. Tox21_111411
60. S5671
61. Akos015961167
62. Amcinonide 100 Microg/ml In Methanol
63. Ccg-221135
64. Cs-4805
65. Db00288
66. Nsc 758620
67. Ncgc00021193-03
68. 16alpha,17alpha-(cyclopentane-1,1-diyldioxy)-9-fluoro-11beta-hydroxy-3,20-dioxopregna-1,4-dien-21-yl Acetate
69. Ac-13190
70. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-(cyclopentylidenebis(oxy))-9-fluoro-11-hydroxy-, (11beta,16alpha)-
71. Cas-51022-69-6
72. D01387
73. Sr-01000003161
74. Q4742041
75. Sr-01000003161-2
76. Brd-k13960744-001-09-7
77. Amcinonide, United States Pharmacopeia (usp) Reference Standard
78. 5,6-dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)ethyl]-1h-indolehydrochloride
79. 2-((6a's,6b'r,7's,8a's,8b's,11a'r,12a's,12b's)-6b'-fluoro-7'-hydroxy-6a',8a'-dimethyl-4'-oxo-2',4',6a',6b',7',8',8a',8b',11a',12',12a',12b'-dodecahydro-1'h-spiro[cyclopentane-1,10'-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxole]-8b'-yl)-2-oxoethyl Acetate
80. 2-[(1's,2's,4'r,8's,9's,11's,12'r,13's)-12'-fluoro-11'-hydroxy-9',13'-dimethyl-16'-oxo-5',7'-dioxaspiro[cyclopentane-1,6'-pentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosane]-14',17'-dien-8'-yl]-2-oxoethyl Acetate
| Molecular Weight | 502.6 g/mol |
|---|---|
| Molecular Formula | C28H35FO7 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 502.23668161 g/mol |
| Monoisotopic Mass | 502.23668161 g/mol |
| Topological Polar Surface Area | 99.1 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 1090 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Amcinonide |
| PubMed Health | Amcinonide (Topical application route) |
| Drug Classes | Adrenal Glucocorticoid, Corticosteroid, Strong |
| Drug Label | The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.Each gram of Amcinonide Ointment USP, 0.1% contains 1 mg of the active steroid amcinonide in a specially formulated base... |
| Active Ingredient | Amcinonide |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Fougera Pharms; Taro Pharm Inds |
| 2 of 2 | |
|---|---|
| Drug Name | Amcinonide |
| PubMed Health | Amcinonide (Topical application route) |
| Drug Classes | Adrenal Glucocorticoid, Corticosteroid, Strong |
| Drug Label | The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.Each gram of Amcinonide Ointment USP, 0.1% contains 1 mg of the active steroid amcinonide in a specially formulated base... |
| Active Ingredient | Amcinonide |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Fougera Pharms; Taro Pharm Inds |
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
FDA Label
Amcinonide is a topical corticosteroid. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Amcinonide reduces or inhibits the actions of chemicals in the body that cause inflammation, redness, and swelling. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. When in an ointment form, amcinonide also helps the skin maintain moisture.
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
D07AC11
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07A - Corticosteroids, plain
D07AC - Corticosteroids, potent (group iii)
D07AC11 - Amcinonide
Absorption
Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.
Route of Elimination
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Amcinonide has affinity for the glucocorticoid receptor. It has weak affinity for the progesterone receptor, and virtually no affinity for the mineralocorticoid, estrogen, or androgen receptors.
LOOKING FOR A SUPPLIER?
